(Press-News.org) MILWAUKEE, WI and CAMBRIDGE, MA – January 7, 2026 – The American Society of Gene & Cell Therapy (ASGCT), the leading professional organization for the advancement of cell and gene therapies (CGTs), and the Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on completing development and enabling access to stalled rare disease treatments, today announced a partnership to establish CGTxchange, a jointly owned entity that will serve as a clearinghouse and marketplace for deprioritized CGTs.
The new joint venture will address a growing and urgent challenge facing the CGT field: policy and economic shifts in recent years have led biopharma sponsors to halt development of hundreds of CGTs no longer considered commercially viable by traditional industry standards, including many that delivered clear benefits to patients in trials.
CGTxchange leverages the combined capabilities of the organizations in an unprecedented way to engage a broad array of potential partners and funders to efficiently identify, evaluate, finance, develop, and provide sustainable, reliable, and scalable access to potentially transformative CGTs for ultra-rare diseases.
“At ASGCT, we have observed that a host of cell and gene therapies are being set aside not because they lack clinical merit, but rather due to the challenges of commercializing these therapies once approved,” said David Barrett, CEO of ASGCT. “In partnership with OTXL, we are creating an entirely new way to ensure these CGTs find their way to organizations – whether companies, non-profits or academic institutions – that are ready to take on the challenges of development and commercialization so patients may ultimately benefit.”
Using OTXL’s AI-based platform, CGT assets and related information can be input into a secure, searchable database and analyzed, generating listings and profiles of shelved therapies and providing risk-based assessments. From there, listed assets can be matched with prospective investors or partners in the marketplace, thereby expanding the potential to secure funding and new clinical sponsors.
“Typical venture capital and biopharma expectations for returns are set well above what most CGTs for ultra-rare diseases can meet in light of recent policy and market shifts,” said Craig Martin, CEO of OTXL. “Yet many of these shelved therapies can still offer meaningful returns to the right partners, as well as tremendous benefits to patients. This partnership allows us to surface high-quality, clinical-stage CGT programs to investors and organizations whose missions, timelines and objectives align with what these therapies can deliver.”
Within the partnership, ASGCT will convene and engage its extensive network of CGT leaders, experts, donors and investors, while helping establish CGTxchange as the leading solution for currently ‘pre-viable’ CGT programs. OTXL will develop the platform for the clearinghouse and marketplace, contributing resources from its AI-based infrastructure and partner network to continue to build, adapt and scale the platform for CGT community adoption and use.
ASGCT and OTXL will initiate development of CGTxchange in early 2026, with a targeted mid-year launch and rollout.
About ASGCT
The American Society of Gene & Cell Therapy (ASGCT) is the premier professional organization for scientists, physicians, and patient advocates working to advance the understanding, development, and application of genetic and cellular therapies. With members in more than 60 countries worldwide, ASGCT is committed to the alleviation of human disease through its extensive educational offerings, active engagement in public policy, and a wide array of support resources.
About the Orphan Therapeutics Accelerator
The Orphan Therapeutics Accelerator (OTXL) is a non-profit biotech focused on obtaining, completing development, and enabling commercial access to promising clinical-stage therapies for ultra-rare conditions that have been shelved for financial or strategic reasons. OTXL utilizes alternative development and financing models to advance programs efficiently and sustainably, with proceeds reinvested to support additional rare disease therapies.
###
For further information, contact:
Sarah Kikkert, director of communications
American Society of Gene & Cell Therapy
skikkert@asgct.org, (262) 649-4914
END
American Society of Gene & Cell Therapy and Orphan Therapeutics Accelerator partner to advance and commercialize promising rare disease treatments
First-of-its-kind venture to facilitate and catalyze development of deprioritized cell and gene therapies, supported by AI-enabled platform
2026-01-07
ELSE PRESS RELEASES FROM THIS DATE:
One in 14 patients having day case surgery have new or worse chronic pain 3 months after their operation
2026-01-07
Two new studies published in Anaesthesia (the journal of the Association of Anaesthetists) analysing pain and other factors connected with day surgery in the UK show that around 1 in 8 patients having day-case surgery end up not going home and instead are admitted to hospital for various complications. Furthermore, one in 14 go on to develop chronic pain at the operative site after the procedure.
The studies are by Dr Martha Belete, Torbay and South Devon NHS Foundation Trust, Torbay, Devon, UK and Dr Adam Brayne, University Hospitals Plymouth NHS Trust, ...
New study highlights link between eviction rates and gun violence
2026-01-07
Violent crime has fallen to historic lows in Chicago, although gun violence continues to plague neighborhoods with concentrated poverty. A 2023 study of five major cities showed that more than 55% of shootings occurred in just 9% of total census tracts, and that small increases in things like poverty, unemployment, or limited access to health care are associated with large increases in firearm violence.
Yet not every neighborhood that struggles with these challenges also has high rates of violence. ...
Heatwaves heat up soil but not toxin levels in rice, study finds
2026-01-07
In a surprising twist amid rising climate concerns, new research shows that scorching soil temperatures during extreme heatwaves do not necessarily boost the uptake of toxic elements like arsenic in rice crops. This finding, from a real world experiment during China's record breaking 2022 heatwaves, challenges fears that global warming will poison staple foods.
"Our study reveals that soil warming alone, decoupled from air temperature rises, does not inevitably ramp up arsenic or heavy metal accumulation in rice grains," said Sha Zhang, ...
Digital modeling reveals where construction carbon emissions really come from
2026-01-07
A new study shows how digital building models can be used to pinpoint where carbon emissions occur across a building’s entire life cycle, offering designers and policymakers a powerful tool to reduce the climate footprint of the construction industry.
Researchers developed an integrated method that combines Building Information Modeling and Life Cycle Assessment to calculate carbon emissions from the earliest design stage through construction, operation, and eventual demolition. Using a real office building in China as a case study, the team demonstrated how emissions can be quantified in detail and how targeted reduction ...
Turning farm waste into water filters
2026-01-07
Researchers at the University of Delaware have transformed discarded corn cobs and other agricultural byproducts into high performance biochar filters that capture both ammonia and tiny plastic particles from water. In laboratory tests, optimized biochar removed up to 64 percent of dissolved ammonia and more than 97 percent of polystyrene micro and nanoplastics without leaching harmful chemicals back into the water. The study points to a practical way to clean polluted water while recycling agricultural waste and locking ...
New study shows how the spleen helps the immune system accept a transplant
2026-01-07
MINNEAPOLIS/ST. PAUL (1/07/2026) —New research from the University of Minnesota Medical School offers a new view of how the immune system responds to organ transplants. The findings, published today in Science Advances External link that opens in the same window, show that T cell exhaustion – traditionally viewed as a pathological failure of the immune system — can instead play a protective role by helping the body tolerate a donated organ.
The study identifies the spleen as a key control center for transplant tolerance. Researchers found that administering apoptotic donor leukocytes (ADLs) triggers the expansion of donor-specific regulatory T cells, ...
New Mayo Clinic study advances personalized prostate cancer education with an EHR-integrated AI agent
2026-01-07
PHOENIX — Mayo Clinic researchers have developed and evaluated MedEduChat, an electronic health record (EHR) that works with a large language model to provide accurate, patient-specific prostate cancer education.
The findings are published in Nature Portfolio Digital Medicine and highlight a new approach to delivering timely, individualized guidance for people navigating a prostate cancer diagnosis.
Cancer patients often face uncertainty as they process complex information about their diagnosis and treatment options. Limited time with ...
Researchers identify novel therapeutic target to improve recovery after nerve injury
2026-01-07
Peripheral nerve injury reduces the ability of macrophages to clear dead or dying cells – a process known as efferocytosis – leading to chronic pain
Restoring efferocytosis ability reduced neuropathic pain in lab models
Efferocytosis is a potential therapeutic target for chronic neuropathic pain
Researchers at The University of Texas MD Anderson Cancer Center have discovered that targeting a specific immune process could help improve recovery after nerve injury and reduce chronic pain.
The study, published in Proceedings of the National Academy of Sciences (PNAS), was led by Peter Grace, Ph.D., associate ...
Microbes in breast milk help populate infant gut microbiomes
2026-01-07
Most conversations about breast milk tend to focus on topics like nutrients, antibodies and bonding time rather than bacteria. But it turns out that human milk carries its own tiny community of microbes, and those passengers may help shape a baby’s developing gut microbiome — which in turn can impact nutrient absorption, metabolic regulation, immune system development, and more.
A new study published in Nature Communications provides one of the most detailed portraits yet of how different combinations of bacteria in human milk contribute to the assembly of infants’ ...
Reprogramming immunity to rewrite the story of Type 1 diabetes
2026-01-07
In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a bold new front. With $1 million in funding from Breakthrough T1D, the leading global T1D research and advocacy organization, Leonardo Ferreira, Ph.D., assistant professor of Pharmacology and Immunology, and his collaborators at partnering institutions will explore a new approach to treating – and potentially curing – the disease.
The team aims to reimagine how the immune system interacts with the pancreas by combining stem cell biology, immunology and transplantation science. The project’s goal is deceptively simple: to restore beta cell ...
LAST 30 PRESS RELEASES:
Top recognition awarded to 11 stroke researchers for science, brain health contributions
New paper proposes a framework for assessing the trustworthiness of research
Porto Summit drives critical cooperation on submarine cable resilience
University of Cincinnati Cancer Center tests treatment using ‘glioblastoma-on-a-chip’ and wafer technology
IPO pay gap hiding in plain sight: Study reveals hidden cost of ‘cheap stock’
It has been clarified that a fungus living in our body can make melanoma more aggressive
Paid sick leave as disease prevention
Did we just see a black hole explode? Physicists at UMass Amherst think so—and it could explain (almost) everything
Study highlights stressed faults in potential shale gas region in South Africa
Human vaginal microbiome is shaped by competition for resources
Test strip breakthrough for accessible diagnosis
George Coukos appointed director of new Ludwig Laboratory for Cell Therapy
SCAI expert opinion explores ‘wire-free’ angiography-derived physiology for coronary assessment
‘Masculinity crisis’: Influencers on social media promote low testosterone to young men, study finds
Pensoft and ARPHA integrate Prophy to speed up reviewer discovery across 90+ scholarly journals
Accurately predicting Arctic sea ice in real time
A hearing test for the world’s rarest sea turtle
Estimated effectiveness of 2024-2025 COVID-19 vaccination against severe COVID-19
Risk of cardiorespiratory events following RSV–related hospitalization
Socioeconomic status and postpartum depression risk by state trigger laws after dobbs
Shared purpose outperforms specialization, new study shows
Dr. Barron Bichon promoted to vice president of SwRI’s Mechanical Engineering Division
Risk for Lyme disease in Ohio is equal to Connecticut, study shows
Korea University College of Medicine Physician-Scientist Training Program hosts International Symposium and Inauguration Ceremony
Crohn’s & Colitis Foundation survey finds 93% of IBD community supports predictive testing and prevention strategies
New therapy could make life better for kidney transplant patients
Shrinking shellfish? FAU study uncovers acidic water risks in Indian River lagoon
CT scans unwrap secrets of ancient Egyptian life
Clinical data gaps keeping life-saving antibiotics from children
For people with traumatic brain injury and their caregivers, recovery of basic communication is an “acceptable” outcome
[Press-News.org] American Society of Gene & Cell Therapy and Orphan Therapeutics Accelerator partner to advance and commercialize promising rare disease treatmentsFirst-of-its-kind venture to facilitate and catalyze development of deprioritized cell and gene therapies, supported by AI-enabled platform